Results 31 to 40 of about 5,025 (229)

Real-world experience with mechlorethamine gel in patients with mycosis fungoides-cutaneous lymphoma: Preliminary findings from a prospective observational study [PDF]

Journal of American Academy of Dermatology, 2020
Ellen J. Kim, Larisa J. Geskin, Joan Guitart, Christiane Querfeld, Michael Girardi, Amy Musiek, David R. Mink, Michael J. M. Williams, James T. Angello, William L. Bailey   +9 more
openalex   +2 more sources

Management of Mycosis Fungoides with Topical Chlormethine/Mechlorethamine Gel: A Columbia University Cutaneous Lymphoma Center Experience

Acta Dermato-Venereologica, 2021
Mycosis fungoides is a type of cutaneous T-cell lymphoma, which accounts for the majority of cases of cutaneous T-cell lymphoma. Mycosis fungoides can be classified as early-stage (IA–IIA) or late-stage (IIB or greater) disease.
Tiffany J. Garcia-Saleem, Connor J. Stonesifer, A. Khaleel, Larisa J. Geskin   +3 more
openalex   +2 more sources

Ebselen oxide attenuates mechlorethamine dermatotoxicity in the mouse ear vesicant model [PDF]

Drug and chemical toxicology (New York, N.Y. 1978), 2018
Mechlorethamine (HN2) is an alkylating agent and sulfur mustard mimetic. Topical exposure to HN2 is associated with tissue blistering. Previous work in our laboratory has shown that ebselen (EB-1) possesses anti-vesicant, anti-inflammatory, anti ...
Hemanta C Rao Tumu, Benedette J. Cuffari, Maria A. Pino, Jerzy Palus, Magdalena Pįętka-Ottlik, Blasé Billack   +5 more
openalex   +2 more sources

Lack of Systemic Absorption of Topical Mechlorethamine Gel in Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma

Journal of Investigative Dermatology, 2021
Christiane Querfeld, Larisa J. Geskin, Ellen J. Kim, Julia Scarisbrick, Pietro Quaglino, Evangelia Papadavid, James T. Angello, Pablo L. Ortiz‐Romero   +7 more
openalex   +2 more sources

Mechlorethamine Hydrochloride Gel in the Treatment of Mycosis Fungoides–Type Cutaneous T-Cell Lymphoma (MF-CTCL): A Focus on Patient Selection and Special Considerations

Cancer Management and Research, 2022
Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma (CTCL) and often has an indolent course, particularly for patients presenting with early-stage (patch/plaque) disease.
Caitlin Crimp, Ameya Gangal, Erica S. Tarabadkar, Michi M. Shinohara   +3 more
openalex   +3 more sources

Topical mechlorethamine for cutaneous T-cell lymphoma: a historical perspective

EJC Skin Cancer
Balázs Nagy, Norbert Kovács, Katinka Ónodi, Ildikó Csányi, Erika Varga, Henriette Ócsai, Judit Oláh, Rolland Gyulai, Eszter Baltás   +8 more
openalex   +2 more sources

Mechlorethamine Oxide Hydrochloride [PDF]

Definitions, 2020

openalex   +2 more sources

Randomized Mechlorethamine/Chlormethine Induced Dermatitis Assessment Study (MIDAS) Establishes Benefit of Topical Triamcinolone 0.1% Ointment Cotreatment in Mycosis Fungoides

Dermatologic Therapy, 2022
Treatment of early-stage mycosis fungoides (MF) requires safe, skin-directed therapies. Medication side effects can lead to underutilization of effective therapies.
Carolina V Alexander-Savino, C. Chung, Elaine S. Gilmore, S. M. Carroll, B. Poligone   +4 more
semanticscholar   +1 more source

Carcinogenicity of topical mechlorethamine in mice

Journal of the American Academy of Dermatology, 1992
Herschel S. Zackheim
openaire   +3 more sources

060 Mechlorethamine-Induced Contact Dermatitis Avoidance Study (MIDAS): Preliminary Results [PDF]

Journal of Investigative Dermatology, 2019
Elaine S. Gilmore, Carolina V. Alexander‐Savino, S. Secor-Socha, Brian Poligone   +3 more
openalex   +2 more sources